QUALITY OF LIFE AND ASSOCIATED FACTORS IN ELDERLY PEOPLE WITH MULTIPLE MYELOMA TREATED IN THE UNIFIED HEALTH SYSTEM (SUS)
DOI:
https://doi.org/10.56238/arev7n9-072Keywords:
Aged, Multiple Myeloma, Quality of LifeAbstract
Multiple Myeloma (MM) is a plasma cell cancer that mainly affects the elderly population, with an average age of 70 years. It represents around 2% of cancers and ranks second among hematological neoplasms. Despite the improvement in survival of individuals with MM, it is still an incurable pathology marked by relapses and remissions. Impacts of the disease on the Health-Related Quality of Life (HRQoL) of these elderly people are observed. In patients living with cancer, the factors that negatively affect HRQoL, when minimized, lead to better clinical outcomes. The present study aimed to evaluate HRQOL and associated factors in elderly people with MM in first line of treatment or relapses, treated at the Hospital das Clínicas of the Federal University of Pernambuco (HC-UFPE). This is a cross-sectional, quantitative study where participants were characterized from a sociodemographic and clinical point of view and comparisons were made with HRQoL scores. HRQoL was assessed using the following questionnaires: Quality of Life Questionnaire of European Organization Research for Treatment of Cancer (EORTC-QLQ C-30) and Quality of Life Questionnaire of Multiple Myeloma-20 (EORTC QLQ-MY20). Of the 27 patients included, the majority are between 60 and 69 years old, are black, married, have low education, IgG Kappa subtype, less than 5 years of illness, submitted to only one line of treatment, with no history of Bone Marrow Transplant (BMT), present multimorbidity and polypharmacy, good performance status index and advanced staging. Low education, widowed/divorced, multimorbidity and worse Performance Status demonstrated significant deterioration in HRQoL. Contemplating and controlling the multifactorial aspects of elderly people with MM are strategies to improve HRQoL.
Downloads
References
AGUIAR, C. C. T. et al. Instrumentos de avaliação de qualidade de vida relacionada à saúde no diabetes melito. Arq. Bras. Endocrinol. Metab., [s. l.], v. 52, n. 6, p. 931939, 2008. DOI: https://doi.org/10.1590/S0004-27302008000600004
ALOBAIDI, A. et al. Depressive symptoms, mental health-related quality of life, and survival among older patients with multiple myeloma. Support Care Cancer, Berlin, v. 28, N. 9, p. 4097-4106, 2020. DOI 10.1007/s00520-019-05246-6. DOI: https://doi.org/10.1007/s00520-019-05246-6
BRANAGAN, A. et al. Current treatment strategies for Multiple Myeloma. JCO Oncol Pract, Alexandria, v. 16, n. 1, p. 5-14, 2020. DOI 10.1200/JOP.19.00244. DOI: https://doi.org/10.1200/JOP.19.00244
BRASIL. Ministério da Saúde. Secretaria de Ciência, Tecnologia, Inovação e
Insumos Estratégicos em Saúde. Departamento de Gestão e Incorporação de Tecnologias e Inovação em Saúde. Coordenação-Geral de Gestão de Tecnologias em Saúde. Coordenação de Gestão de Protocolos Clínicos e Diretrizes Terapêuticas. Diretrizes diagnósticas e terapêuticas do mieloma múltiplo. Brasília: Conitec, 2022.
BRASIL. Ministério da Saúde. Tabnet: painel oncologia Brasil. [Brasília]: DATASUS,
2023. Disponível em: http://tabnet.datasus.gov.br/cgi/dhdat.exe?PAINEL_ ONCO/PAINEL_ONCOLOGIABR.def. Acesso em: 22 abr. 2023.
BRASIL. Ministério da Saúde; INCA. Estimativa 2018: incidência de câncer no Brasil. Rio de Janeiro: INCA, 2018.
CAMPOS, J. A. D. B. et al. European organization for research and treatment of cancer quality of life questionnaire core 30: factorial models to Brazilian cancer patients. Einstein, São Paulo, v. 16, n. 1, 2018. DOI 10.1590/S167945082018AO4132. DOI: https://doi.org/10.1590/s1679-45082018ao4132
CDC. Myeloma basics. [S. l.]: U. S. Center for Disease Control and Prevention,
2022. Disponível em: https://www.cdc.gov/cancer/myeloma/index.htm. Acesso em: 20 maio 2022.
COCKS, K. et al. An international field study of the reliability and validity of a diseasespecific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer, Oxford, v. 43, n. 11, p. 1670-1678, 2007. DOI 10.1016/j.ejca.2007.04.022. DOI: https://doi.org/10.1016/j.ejca.2007.04.022
COSTA, L. J. et al. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv, Washington, v. 1, n. 4, p. 282287, 2017. DOI 10.1182/bloodadvances.2016002493. DOI: https://doi.org/10.1182/bloodadvances.2016002493
COWAN, A. J. et al. Global Burden of Multiple Myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol, Chicago, v. 4, n. 9, p. 12211227, 2018. DOI 10.1001/jamaoncol.2018.2128. DOI: https://doi.org/10.1200/JCO.2018.36.15_suppl.e20023
DESPIÉGEL, N. et al. Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France. Clin Lymphoma Myeloma Leuk, Dallas, v. 19, n. 1, p. e13-e28, 2019. DOI 10.1016/j.clml.2018.08.019. DOI: https://doi.org/10.1016/j.clml.2018.08.019
DIMOPOULOS, M. A. et al. Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. Leuk Lymphoma, Philadelphia, v. 55, n. 7, p. 14891497, 2014. DOI 10.3109/10428194.2013.847933. DOI: https://doi.org/10.3109/10428194.2013.847933
DOWLING, M.; KELLY, M.; MEENAGHAN, T. Multiple myeloma: managing a complex blood cancer. Br J Nurs, London, v. 25, n. 16, p. 18-28, 2016. DOI 10.12968/bjon.2016.25.S18. DOI: https://doi.org/10.12968/bjon.2016.25.S18
ENGELHARDT, M. et al. Real-world evaluation of health-related quality of life in patients with multiple myeloma from Germany. Clin Lymphoma Myeloma Leuk, Dallas, v. 21, n. 2, p. e160-e175, 2021. DOI 10.1016/j.clml.2020.10.002. DOI: https://doi.org/10.1016/j.clml.2020.10.002
FAYERS, P. M.; MACHIN, D. Quality of life: the assessment, analysis and reporting of patient-reported outcomes. 3rd ed. Hoboken: Wiley Blackwell. 2016. DOI: https://doi.org/10.1002/9781118758991
GORDIA, A. P. et al. Qualidade de vida: contexto histórico, definição, avaliação e fatores associados. Revista brasileira de qualidade de vida, [s. l.], v. 3, n. 1, 2011. DOI 10.3895/S2175-08582011000100005. DOI: https://doi.org/10.3895/S2175-08582011000100005
GUEDES, A.; BECKER, R. G.; TEIXEIRA, L. E. M. Mieloma múltiplo (Parte 1): atualização sobre epidemiología, critérios diagnósticos, tratamento sistêmico e prognóstico. Rev Bras Ortop, São Paulo, v. 58, n. 3, p. 361-367, 2023. 10.1055/s0043-1770149. DOI: https://doi.org/10.1055/s-0043-1770149
GUTHRIE, B. et al. The rising tide of polypharmacy and drug-drug interactions:
population database analysis. BMC Med, London, v. 13, p. 74, 2015. DOI 10.1186/s12916-015-0322-7.
HARRISON, C. et al. Examining different measures of multimorbidity, using a large prospective cross-sectional study in Australian general practice. BMJ Open, London, v. 11, n. 4, 2014. DOI 10.1136/bmjopen-2013-004694. DOI: https://doi.org/10.1136/bmjopen-2013-004694
HASANVAND, S. et al. A critical review of instruments measuring the quality of life of cancer patients in Iranian studies and their psychometrics properties. Asian Pac J Cancer Prev, Bangkok, v. 20, n. 2, p. 333-343, 2019. DOI 10.31557/APJCP.2019.20.2.333. DOI: https://doi.org/10.31557/APJCP.2019.20.2.333
HILLENGASS J. et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol, London, v. 20, n. 6, p. e302-e312, 2019. DOI 10.1016/S1470-2045(19)30309-2. DOI: https://doi.org/10.1016/S1470-2045(19)30309-2
HU, H. X. et al. Health-related quality of life in patients with multiple myeloma in relation to line of treatment and response. In: Annual European Hematology Association Congress, 21., 2016, Copenhagen. Abstract book [...]. Copenhagen: European Hematology Association, 2016. p. 603, E1459.
HUNGRIA, V. T. M. Doença óssea em Mieloma Múltiplo. Rev. Bras. Hematol. Hemoter, [s. l.], v. 29, n. 1, p. 60-66, 2007. DOI: https://doi.org/10.1590/S1516-84842007000100013
JACOBSEN, P. B.; JIM, H. S. L. Consideration of quality of life in cancer survivorship research. Cancer Epidemiol Biomarkers Prev, Philadelphia, v. 20, n. 10, p. 20352041, 2011. DOI 10.1158/1055-9965.EPI-11-0563. DOI: https://doi.org/10.1158/1055-9965.EPI-11-0563
JENSEN, C. E. et al. Physical function, psychosocial status, and symptom burden among adults with plasma cell disorders and associations with quality of life.
Oncologist, Dayton, v. 27, n. 8, p. 694-702, 2022. DOI 10.1093/oncolo/oyac079.
KUMAR, S. K. et al. Multiple myeloma. Nat Rev Dis Primers, London, v. 3, n. 1, p. 17046, 2017. DOI 10.1038/nrdp.2017.46. DOI: https://doi.org/10.1038/nrdp.2017.46
KUMAR, S.K. et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood, New York, v. 111, n. 5, p. 2516-2520, 2008. DOI 10.1182/blood2007-10-116129. DOI: https://doi.org/10.1182/blood-2007-10-116129
LAKSHMI, H. K. et al. A prospective single-arm study of Melphalan, Prednisolone and Lenalidomide (MPL) as first line treatment in elderly patients with multiple myeloma: an institutional study. Indian J Med Paediatr Oncol, [s. l.], v. 43, n. 05, p. 409-414, 2022. DOI 10.1055/s-0042-1748802. DOI: https://doi.org/10.1055/s-0042-1748802
LEI, M. et al. Current management and emerging treatment strategies for multiple myeloma. Rinsho Ketsueki, Tokyo, v. 60, n. 9, p. 1243-1256, 2019. DOI 10.11406/rinketsu.60.1243.
LOBO, T. C. O atual cenário da mortalidade do mieloma múltiplo no Brasil. São Paulo: Observatório de Oncologia, 23 mar. 2018. Disponível em: https://observatoriodeoncologia.com.br/estudos/cancer-de-sangue/mielomamultiplo/2018/o-atual-cenario-da-mortalidade-do-mieloma-multiplo-no-brasil/. Acesso em: 24 jul. 2024.
LUDWIG, H. et al. Health-related quality of life in the ENDEAVOR study: carfilzomibdexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J, New York, v. 9, n. 23, p. 23, 2019. DOI 10.1038/s41408019-0181-0. DOI: https://doi.org/10.1038/s41408-019-0181-0
LUDWIG, H. et al. Patient‐reported pain severity and health‐related quality of life in patients with multiple myeloma in real world clinical practice. Cancer Rep, Hoboken, v. 5, n. 1, p. e1429, 2022. DOI 10.1002/cnr2.1429. DOI: https://doi.org/10.1002/cnr2.1429
MACHADO, L. et al. Evolução do status de performance, índice de massa corpórea e distância percorrida no teste de caminhada de seis minutos em pacientes com câncer de pulmão avançado submetidos à quimioterapia. J Bras Pneumo, São Paulo. v. 36, n. 5, p. 588-594, 2010. DOI 10.1590/S1806-37132010000500010. DOI: https://doi.org/10.1590/S1806-37132010000500010
MACHADO, T. R. L. Utilização de medicamentos por idosos com mieloma múltiplo: análise na perspectiva da atenção ao idoso. 2021. 96 f. Dissertação (Mestrado em Medicamentos e Assistência Farmacêutica) – Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, 2021.
MALTA, J. S. et al. Validity and reliability of the QLQ-MY20 module for assessing the health-related quality of life in Brazilians with multiple myeloma. Curr Med Res Opin, London, v. 37, n. 7, p. 1163-1169, 2021. DOI 10.1080/03007995.2021.1929136. DOI: https://doi.org/10.1080/03007995.2021.1929136
MAYO, N. Dictionary of quality of life and health outcomes measurement. Milwaukee: International Society for Quality of Life Research, 2015.
MEDICAL MASTERCLASS CONTRIBUTORS; FIRTH, J. Haematology: multiple myeloma. Clin Med, London, v. 19, n. 1, p. 58-60, 2019. DOI 10.7861/clinmedicine.19-1-58. DOI: https://doi.org/10.7861/clinmedicine.19-1-58
MIAN, H. et al. Geriatric assessment and quality of life changes in older adults with newly diagnosed multiple myeloma undergoing treatment. J Geriatr Oncol, Amsterdam, v. 11, n. 8, p. 1279-1284, 2020. DOI 10.1016/j.jgo.2020.05.004. DOI: https://doi.org/10.1016/j.jgo.2020.05.004
NABULSI, N. A. et al. Self-reported health and survival in older patients diagnosed with multiple myeloma. Cancer Causes Control, Oxford, v. 31, n. 7, p. 641-650, 2020. DOI 10.1007/s10552-020-01305-0. DOI: https://doi.org/10.1007/s10552-020-01305-0
NIELSEN, L. K. et al. Strategies to improve patient‐reported outcome completion rates in longitudinal studies. Qual Life Res, Oxford, v. 29, n. 2, p. 335-346, 2020. DOI 10.1007/s11136-019-02304-8. DOI: https://doi.org/10.1007/s11136-019-02304-8
NORONHA, D. D. et al. Qualidade de vida relacionada à saúde entre adultos e fatores associados: um estudo de base populacional. Ciênc. saúde colet., Rio de Janeiro, v. 21, n. 2, p. 463-474, 2016. DOI 10.1590/1413-81232015212.01102015. DOI: https://doi.org/10.1590/1413-81232015212.01102015
OKEN, M. M. et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol, New York, v. 5, n. 6, p. 649-655, 1982. DOI: https://doi.org/10.1097/00000421-198212000-00014
PALUMBO, A. et al. Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J Clin Oncol, New York, v. 33, n. 26, p. 2863-2869, 2015. DOI 10.1200/JCO.2015.61.2267. DOI: https://doi.org/10.1200/JCO.2015.61.2267
PARSONS, J. A. et al. Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study. BMC cancer, London, v. 19, n. 1, p. 264, 2019. DOI 10.1186/s12885-019-5467-x. DOI: https://doi.org/10.1186/s12885-019-5467-x
RAJKUMAR, S. V. Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management. Am J Hematol, New York, v. 93, n. 8, p. 1091-1110, 2018. DOI 10.1002/ajh.25117. DOI: https://doi.org/10.1002/ajh.25117
RAMSENTHALER, C. et al. Symptoms and anxiety predict declining health-related quality of life in multiple myeloma: a prospective, multi-centre longitudinal study. Palliat Med, London, v. 33, n. 5, p. 541-551, 2019. DOI 10.1177/0269216319833588. DOI: https://doi.org/10.1177/0269216319833588
RICHARDSON, P. G. et al. Interpreting clinical trial data in multiple myeloma:
translating findings to the real-world setting. Blood Cancer J, New York, v. 8, n. 11, p. 109, 2018. DOI 10.1038/s41408-018-0141-0.
ROBINSON JR, D. et al. The influence of baseline characteristics and disease stage on health‐related quality of life in multiple myeloma: findings from six randomized controlled trials. Br J Haematol, Oxford, v. 174, n. 3, p. 368-381, 2016. DOI 10.1111/bjh.14058. DOI: https://doi.org/10.1111/bjh.14058
ROSENBERG, P. S.; BARKER, K. A.; ANDERSON, W. F. Future distribution of multiple myeloma in the United States by sex, age, and race/ethnicity. Blood, New York, v. 125, n. 2, p. 410-412, 2015. DOI 10.1182/blood-2014-10-609461. DOI: https://doi.org/10.1182/blood-2014-10-609461
SALEMA, C. L.; CAVALHO, C. Diagnósticos, tratamentos e prognósticos do Mieloma Múltiplo. Rev Ciên Saúde, [s. l.], v. 4, n. 1, p. 1-9, 2019.
SEITZLER, S. et al. Quality of life in multiple myeloma: considerations and recommendations. Expert Rev Hematol, London, v. 12, n. 6, p. 419-424, 2019. DOI 10.1080/17474086.2019.1613886. DOI: https://doi.org/10.1080/17474086.2019.1613886
SITLINGER, A.; ZAFAR, S. Y. Health-related quality of life: the impact on morbidity and mortality. Surg Oncol Clin N Am, Philadelphia, v. 27, n. 4, p. 675-684, 2018. DOI 10.1016/j.soc.2018.05.008. DOI: https://doi.org/10.1016/j.soc.2018.05.008
SNOWDEN, J. A. et al. Guidelines for screening and management of late and longterm consequences of myeloma and its treatment. Br J Haematol, Oxford, v. 176, n. 6, p. 888-907, 2017. DOI 10.1111/bjh.14514. DOI: https://doi.org/10.1111/bjh.14514
SONNEVELD, P. et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood, New York, v. 127, n. 24, p. 2955-2962, 2016. DOI 10.1182/blood-2016-01-631200. DOI: https://doi.org/10.1182/blood-2016-01-631200
SULLY, K. et al. Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients. Eur J Haematol, Copenhagen, v. 103, n. 5, p. 500-509, 2019. DOI 10.1111/ejh.13316. DOI: https://doi.org/10.1111/ejh.13316
SUNG, H et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, New York, v. 71, n. 3, p. 209-249, 2021. DOI 10.3322/caac.21660. DOI: https://doi.org/10.3322/caac.21660
SUZUKI, N. et al. Symptoms and health-related quality of life in patients with newly diagnosed multiple myeloma: a multicenter prospective cohort study. Jpn J Clin Oncol, Tokyo, v. 52, n. 2, p. 163-169, 2022. DOI 10.1093/jjco/hyab178. DOI: https://doi.org/10.1093/jjco/hyab178
TADELE, N. Evaluation of quality of life of adult cancer patients attending Tikur Anbessa specialized referral hospital, Addis Ababa Ethiopia. Ethiop J Health Sci, Jimma, v. 25, n. 1, p. 53-62, 2015. DOI 10.4314/ejhs.v25i1.8. DOI: https://doi.org/10.4314/ejhs.v25i1.8
VAN DER POEL, M. W. M. et al. Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry. Ann Hematol, Berlin, v. 94, n. 4, p. 651-661, 2015. DOI 10.1007/s00277-014-2264-0. DOI: https://doi.org/10.1007/s00277-014-2264-0
VAN ROIJ, J.; et al. Measuring health-related quality of life in patients with advanced
cancer: a systematic review of self-administered measurement instruments. Qual
Life Res, Oxford, v. 27, n. 8, p. 1937-1955, 2018. DOI 10.1007/s11136-018-1809-4. DOI: https://doi.org/10.1007/s11136-018-1809-4
VENDRUSCULO, L. M. Capacidade funcional e qualidade de vida de mulheres com câncer de mama após o tratamento oncológico. 2011. Dissertação (Mestrado em Enfermagem em Saúde Pública) – Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, 2011.
WARSAME, R; D’SOUZA, A. Patient reported outcomes have arrived: a practical overview for clinicians in using patient reported outcomes in oncology. Mayo Clin Proc, Rochester, v.94, n. 11, p. 2291-2301, 2019. DOI 10.1016/j.mayocp.2019.04.005. DOI: https://doi.org/10.1016/j.mayocp.2019.04.005
WENT, M. et al. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat Commun, London, v. 9, n. 1, p. 3707, 2018. DOI 10.1038/s41467-018-04989-w.
WILLAN, J. et al. Multiple myeloma in the very elderly patient: challenges and solutions. Clin Interv Aging, Auckland, v. 11, p. 423-435, 2016. DOI 10.2147/CIA.S89465. DOI: https://doi.org/10.2147/CIA.S89465
